These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28902675)

  • 1. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.
    Riazi S; Kraeva N; Hopkins PM
    Anesthesiology; 2018 Jan; 128(1):168-180. PubMed ID: 28902675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.
    Riazi S; Kraeva N; Muldoon SM; Dowling J; Ho C; Petre MA; Parness J; Dirksen RT; Rosenberg H
    Can J Anaesth; 2014 Nov; 61(11):1040-9. PubMed ID: 25189431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms.
    Capacchione JF; Sambuughin N; Bina S; Mulligan LP; Lawson TD; Muldoon SM
    Anesthesiology; 2010 Jan; 112(1):239-44. PubMed ID: 20010423
    [No Abstract]   [Full Text] [Related]  

  • 4. RYR1-Related Rhabdomyolysis: A Spectrum of Hypermetabolic States Due to Ryanodine Receptor Dysfunction.
    Kruijt N; den Bersselaar LV; Snoeck M; Kramers K; Riazi S; Bongers C; Treves S; Jungbluth H; Voermans N
    Curr Pharm Des; 2022; 28(1):2-14. PubMed ID: 34348614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetics of malignant hyperthermia.
    Brandom BW
    Anesthesiol Clin North Am; 2005 Dec; 23(4):615-9, viii. PubMed ID: 16310654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.
    van den Bersselaar LR; Hellblom A; Gashi M; Kamsteeg EJ; Voermans NC; Jungbluth H; de Puydt J; Heytens L; Riazi S; Snoeck MMJ
    Anesthesiology; 2022 Jun; 136(6):940-953. PubMed ID: 35285867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.
    Dlamini N; Voermans NC; Lillis S; Stewart K; Kamsteeg EJ; Drost G; Quinlivan R; Snoeck M; Norwood F; Radunovic A; Straub V; Roberts M; Vrancken AF; van der Pol WL; de Coo RI; Manzur AY; Yau S; Abbs S; King A; Lammens M; Hopkins PM; Mohammed S; Treves S; Muntoni F; Wraige E; Davis MR; van Engelen B; Jungbluth H
    Neuromuscul Disord; 2013 Jul; 23(7):540-8. PubMed ID: 23628358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible.
    McKenney KA; Holman SJ
    Anesthesiology; 2002 Mar; 96(3):764-5. PubMed ID: 11873057
    [No Abstract]   [Full Text] [Related]  

  • 9. The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis: A study protocol.
    van den Bersselaar LR; Kruijt N; Scheffer GJ; van Eijk L; Malagon I; Buckens S; Custers JA; Helder L; Greco A; Joosten LA; van Engelen BG; van Alfen N; Riazi S; Treves S; Jungbluth H; Snoeck MM; Voermans NC
    Medicine (Baltimore); 2021 Aug; 100(33):e26999. PubMed ID: 34414986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees.
    Davis M; Brown R; Dickson A; Horton H; James D; Laing N; Marston R; Norgate M; Perlman D; Pollock N; Stowell K
    Br J Anaesth; 2002 Apr; 88(4):508-15. PubMed ID: 12066726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
    Kraeva N; Sapa A; Dowling JJ; Riazi S
    Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility.
    Sambuughin N; Capacchione J; Blokhin A; Bayarsaikhan M; Bina S; Muldoon S
    Clin Genet; 2009 Dec; 76(6):564-8. PubMed ID: 19807743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive diagnosis of malignant hyperthermia susceptibility by genetic testing: A case report.
    Basile E; McGrath K; Jones K; Apostolov BD; Kahana M
    Paediatr Anaesth; 2023 Oct; 33(10):868-869. PubMed ID: 37357724
    [No Abstract]   [Full Text] [Related]  

  • 14. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
    Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
    J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RYR1-related myopathies: a wide spectrum of phenotypes throughout life.
    Snoeck M; van Engelen BG; Küsters B; Lammens M; Meijer R; Molenaar JP; Raaphorst J; Verschuuren-Bemelmans CC; Straathof CS; Sie LT; de Coo IF; van der Pol WL; de Visser M; Scheffer H; Treves S; Jungbluth H; Voermans NC; Kamsteeg EJ
    Eur J Neurol; 2015 Jul; 22(7):1094-112. PubMed ID: 25960145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
    Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
    Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
    [No Abstract]   [Full Text] [Related]  

  • 17. RYR1-related rhabdomyolysis: A common but probably underdiagnosed manifestation of skeletal muscle ryanodine receptor dysfunction.
    Voermans NC; Snoeck M; Jungbluth H
    Rev Neurol (Paris); 2016 Oct; 172(10):546-558. PubMed ID: 27663056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant Hyperthermia, Exertional Heat Illness, and RYR1 Variants: The Muscle May Not Be the Brain.
    Sagui E
    Anesthesiology; 2016 Feb; 124(2):510. PubMed ID: 26785433
    [No Abstract]   [Full Text] [Related]  

  • 19. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Core myopathies and malignant hyperthermia susceptibility: a review.
    Brislin RP; Theroux MC
    Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.